Application of 68Ga-Pentixafor PET/CT for Thymoma

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Chemokine receptor CXCR4 was expressed in T cells and CXCR4-targeting molecular imaging- 68Ga-Pentixafor PET/CT could be a promising technique to evaluate the extent of thymoma with higher accuracy. This prospective study is going to investigate whether metabolic characterization by 68Ga-Pentixafor PET/CT may be superior for diagnosis, distinguish evaluation for thymoma.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Peking Union Medical College Hospital

Criteria

Inclusion Criteria:

• suspected or confirmed untreated thymoma patients

• signed written consent.

Exclusion Criteria:

• pregnancy

• breastfeeding

• known allergy against Pentixafor

• any medical condition that in the opinion of the investigator,may

• significantly interfere with study compliance.